Product
ALIA-1758
1 clinical trial
1 indication
Indication
Alzheimer's diseaseClinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Single Ascending Dose Trial to Assess the Safety, Tolerability and Pharmacokinetic Effects of ALIA-1758 in Healthy ParticipantsStatus: Not yet recruiting, Estimated PCD: 2024-12-01